Search

Search Constraints

You searched for: Author/Creator Cagnetta, Antonia

Search Results

1. A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia. (November 2019)

2. Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas. Issue 1 (2nd January 2020)

3. Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. (23rd January 2018)

4. Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia. (22nd May 2020)

6. Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD‐driven salvage approach. (26th July 2019)

7. Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. (22nd October 2015)

8. Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. (22nd October 2015)

9. Pre‐transplant minimal residual disease assessment and transplant‐related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. (12th August 2021)

10. Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients. Issue 7 (6th June 2020)